Levetiracetam Ucb

Levetiracetam, the active ingredient in Levetiracetam Ucb, is an anticonvulsant presented as an oral tablet for oral use. It is employed to manage partial, generalized tonic‑clonic and myoclonic seizures in patients diagnosed with epilepsy, helping to reduce seizure frequency and improve quality of life.

GNH USA supplies Levetiracetam Ucb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for healthcare providers across multiple regions. All shipments are handled under Good Distribution Practice to ensure product integrity.

Levetiracetam is an antiepileptic drug used to control seizure activity in various epilepsy syndromes. - Partial seizures: Reduces frequency of focal onset seizures, with or without secondary generalization. - Generalized tonic‑clonic seizures: Decreases occurrence of bilateral convulsive seizures in patients with generalized epilepsy. - Myoclonic seizures: Controls rapid, brief muscle jerks characteristic of myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy or sluggish. - Fatigue: persistent lack of energy. - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Irritability: increased agitation or mood swings. - Nausea: upset stomach with urge to vomit. - Blurred vision: temporary loss of visual clarity. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Mood changes: depression, anxiety, or suicidal thoughts. - Hematologic abnormalities: neutropenia, thrombocytopenia, or anemia. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin blistering. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Multiorgan failure: rare but potentially life‑threatening systemic involvement. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose in patients with reduced kidney function. - History of psychiatric disorders: monitor for mood changes or depression. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy: limited data; evaluate risk‑benefit before use. - Elderly patients: start at lower dose and titrate slowly. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: can lower levetiracetam concentrations, risking breakthrough seizures.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system depression, increasing drowsiness. - Other antiepileptic drugs (e.g., valproate, phenytoin): may require dose adjustments. - Oral contraceptives: levetiracetam may slightly reduce hormonal efficacy; consider alternative contraception.